In CRC models, BC administration significantly reduces tissue levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and modulates Hedgehog signaling markers - suppressing SHH, SMO, and Gli1 protein expression while enhancing SUFU protein production. The gene discussed is GLI1; the disease is breast cancer.